Today: 29 April 2026
Browse Category

NYSE:KMX 25 September 2025 - 31 January 2026

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Nasdaq Surges Amid AI Frenzy and Fed Optimism – EA Skyrockets on $50B Buyout Buzz

The Nasdaq Composite closed at 22,484.07 on Sept. 26, up 0.44% for the day but down about 0.7% for the week. Electronic Arts surged 15% on reports of a $50 billion go-private deal, while CarMax plunged 20% after missing Q2 estimates. Navan and Lendbuzz filed for Nasdaq IPOs amid renewed tech IPO activity. Investors await major tech earnings in early October, focusing on AI demand.
28 September 2025
·············
Nasdaq Stumbles as Fed Jitters Mount, Intel Soars, Tariffs Rattle Tech Markets

Nasdaq Stumbles as Fed Jitters Mount, Intel Soars, Tariffs Rattle Tech Markets

U.S. stocks fell for a third straight session Thursday, with the Nasdaq down 0.5% to 22,384.70, erasing recent record highs. Strong economic data—including a Q2 GDP revision to 3.8% and lower jobless claims—pushed Treasury yields and the dollar higher, fueling doubts about near-term Fed rate cuts. Intel surged 9% on investment reports, while Oracle dropped 5% after a “Sell” rating. Trump announced sweeping new tariffs, rattling global pharma stocks.
26 September 2025
·········
Wall Street’s Wild 48 Hours: NYSE Hit by Fed Jitters, Tariff Shocks & Earnings Surprises

Wall Street’s Wild 48 Hours: NYSE Hit by Fed Jitters, Tariff Shocks & Earnings Surprises

U.S. stocks fell for a third straight session, with the Dow closing at 45,947 on Thursday and the S&P 500 and Nasdaq each down about 0.5%. President Donald Trump announced new tariffs, including 100% duties on imported branded pharmaceuticals, rattling global healthcare stocks. Weekly jobless claims dropped to 218,000, and Q2 GDP was revised up to 3.8%, dampening hopes for aggressive Fed rate cuts.
26 September 2025
·····
Hot GDP Surprise Shatters Wall Street’s Rally – Stocks Slide on Fed Jitters (Sept 25, 2025)

Hot GDP Surprise Shatters Wall Street’s Rally – Stocks Slide on Fed Jitters (Sept 25, 2025)

U.S. stocks fell for a third straight session Thursday, with the S&P 500 and Nasdaq down about 0.5% and the Dow off 0.4%. Strong GDP and jobless data fueled doubts over Fed rate cuts, pressuring markets. Health care stocks slumped after a medtech import probe; Intel jumped 9% on Apple stake rumors. Amazon agreed to pay $2.5 billion to settle an FTC lawsuit over Prime memberships.
25 September 2025
············

Stock Market Today

  • Ceres Power Surges Past Rolls-Royce, Nvidia, BP in FTSE 250 Rally
    April 29, 2026, 9:27 AM EDT. Ceres Power (LSE:CWR) leads the FTSE 250 stock gains in 2026 with a staggering 176% rise year-to-date, far outpacing Rolls-Royce, Nvidia and BP. The clean energy tech firm, specializing in licensing advanced solid oxide fuel cell and hydrogen technology, posted a remarkable 933% gain over the last year. Despite declining revenues - £32.6 million in 2025 down from £51.9 million the previous year - and no expected profits in 2026 or 2027, investor enthusiasm is fueled by the AI-driven data center boom. Its recent collaboration with Centrica aims to deploy efficient on-site power solutions swiftly for AI hubs and logistics centers. This positions Ceres as a crucial 'picks and shovels' provider amid the AI energy surge. However, over five years, the stock remains down 55%, prompting debate on its current valuation.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop